Correction: Transparency Notification – PDF of Notification attached

THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS) Acacia Pharma Group plc  1.   Summary of the notification Cambridge, UK and Indianapolis, US – 01 July 2021, 08:00 CEST: Acacia Pharma Group plc has received a transparency notification dated 30 June 2021 indicating that Coltrane Asset Management L.P. now holds, by virtue of the sale of shares on 25 June 2021, 4.86% of the voting rights of the company. Coltrane has therefore crossed the threshold of 5%. 2.   Content of notificationThe notification dated 30 June 2021 contains the following information: Reason of the notification – acquisition or disposal of voting securities or tightsNotification by – a parent undertaking or a controlling person Persons subject to the notification requirement: NameAddress (for legal entities)Mandeep Manku250 W 55th St 16CNew York, NY 10019Coltrane Asset Management Holdings Ltd94 Solaris AvenueCamana Bay, Grand Cayman KY1-1108, Cayman IslandsColtrane Asset Management L.P.94 Solaris AvenueCamana Bay, Grand Cayman KY1-1108, Cayman Islands Date on which the threshold is crossed – 25 June 2021Threshold that is crossed – 5%Denominator – 93,713,951Notified details: A)   Voting rightsPrevious notificationAfter the transaction # of voting rights# of voting rights% of voting rightsHolders of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securitiesMandeep Manku 000.00%0.00%Coltrane Asset Management L.P.4,931,6844,844,40404.86%0.00%Subtotal 4,844,404 4.86%  TOTAL4,844,40404.86%0.00% B)   Equivalent financial instrumentsAfter the transactionHolders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement        TOTAL  00.00%         TOTAL (A+B)  # of voting rights% of voting rights    CALCULATE4,844,4044.86%  Full chain of controlled undertakings through which the holding is effectively held: Coltrane Asset Management, L.P. is an investment advisor which manages funds and accounts which hold the shares reported in this filing.Coltrane Asset Management, L.P. can exercise the voting rights at its discretion, without any instruction from its clients.Coltrane Asset Management, L.P. is controlled by Coltrane Asset Management Holdings, Ltd, which is controlled by Mandeep Manku.  3.   Miscellaneous This press release is available on Acacia Pharma Group plc’s website (https://acaciapharma.com/investors/regulatory-announcements)The notification may be found on Acacia Pharma Group plc’s website ((https://acaciapharma.com/investors/regulatory-announcements) Contacts Acacia Pharma Group plcMike Bolinder, CEOGary Gemignani, CFO+44 1223 919760 / +1 317 505 [email protected] International MediaMark Swallow, Frazer Hall, David DibleMEDiSTRAVA Consulting +44 20 7638 [email protected] InvestorsLifeSci AdvisorsIrina Koffler+1 [email protected] in Belgium and the NetherlandsChris Van Raemdonck+32 499 58 55 31 [email protected] Acacia Pharma Group plcThe Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United KingdomCompany number 9759376 About Acacia Pharma Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV). BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market. APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy. Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com
Attachment

TR-1BE_ACPH BB_06.30.21_ACPH_Signed (002)